This study will evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir
(SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV)
who have received a liver transplant.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02781571
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
History of chronic HCV prior to liver transplant with HCV reoccurrence post-transplant
HCV genotype 1, 2, 3, 4, 5, 6, or indeterminate
Individuals ≥ 3 months post-liver transplant with chronic HCV reoccurrence
Male and nonpregnant/ non-lactating female individuals without cirrhosis or with compensated cirrhosis
Metavir stage 3 or 4 fibrosis/cirrhosis or corresponding fibrosis Key
History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol,
Co-infection with HIV or hepatitis B virus
Known hypersensitivity to study medication,
Use of any prohibited concomitant medications as within with window before the Day 1 visit. NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
All locations for NCT02781571
Hospital Clínic de Barcelona
Hospital Universitari Vall d'Hebron
Reina Sofía University Hospital
Hospital General Universitario Gregorio Maranon
Hospital Ramón Y Cajal
Hospital Universitario Virgen del Rocío
La Fe Hospital
Hospital Clinico Zaragoza
University Hospital Zurich
United Kingdom (5)
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom
St James University Hospital
Leeds, United Kingdom
Kings College Hospital
London, United Kingdom
Royal Free Hampstead NHS Trust
London, United Kingdom
View full eligibility
Tris trial is registered with FDA with number: NCT02781571. The sponsor of the trial is Gilead Sciences and it is looking for 79 volunteers for the current phase.
Official trial title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects With Chronic HCV Infection Who Have Received a Liver Transplant
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!